DSNTV: Good Neighbor Pharmacy execs talk about opportunities for independent pharmacy
LAS VEGAS — There was a lot of good that came out of this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen. A lot of good not only for Good Neighbor Pharmacy operators, but for all of AmerisourceBergen’s stakeholders. Drug Store News sat down with AmerisourceBergen’s top executives to discuss the takeaways from ThoughtSpot 2015 and how this year is positioned to be a year of better opportunities for independents. Click the images below to view the videos.
Drug Store News had the opportunity to sit down with Robert Mauch, President of AmerisourceBergen Drug Corp., at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss how his background as a pharmacist will inform his new role at AmerisourceBergen and the resources AmerisourceBergen is aligning to help independents succeed.
Drug Store News talked with David Neu, President of Good Neighbor Pharmacy, at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss the challenges facing independent pharmacists today and moving from a fee-for-service to an outcomes-based model.
Drug Store News sat down with Christine Lane, Vice President of Good Neighbor Pharmacy, at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss the Elevate Provider Network, the value of Good Neighbor Pharmacy and the organization's new mobile app.
Drug Store News caught up with Peyton Howell, President Global Sourcing and Manufacturer Relations, at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss how manufacturers should think strategically about independent pharmacy and how they can support Good Neighbor Pharmacy to level the playing field.
Drug Store News had the opportunity to speak with Chuck Reed, Group Vice President of Pharmacy and Technology Solutions, at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss how Elevate Provider Network is impacting conversations with payers and how AmerisourceBergen is communicating the value of independent pharmacy to payers.
Drug Store News spoke with Jennifer Zilka, National Director Business Coaching and Pharmacy Ownership at Good Neighbor Pharmacy, at this year’s Good Neighbor Pharmacy ThoughtSpot 2015 conference hosted by AmerisourceBergen to discuss Good Neighbor Pharmacy's Business Coaching, tools pharmacists can use to enhance their business and how AmerisourceBergen enables the utilization of big data.
Express Scripts adds PCSK9 inhibitors to National Preferred Formulary
ST. LOUIS. — Express Scripts this week announced that it would include two new drugs in a new class of cholesterol treatment in its National Preferred Formulary. The PCSK9 inhibitors Repatha (made by Amgen) and Praulent (made by Sanofi and Regeneron), both approved this summer for treatment of certain patients with high cholesterol, will be added to the formulary to ensure that the right patients have access to them.
“Since these new medications were approved a few months ago, our pharmacy experts have worked with medical professionals and our plan sponsors to ensure these drugs are used specifically by patients who will benefit the most,” Express Scripts SVP and chief medical officer Dr. Steve Miller, said. “We are pleased to include both drugs on our National Preferred Formulary, and to put innovative medicines within reach of patients who truly need them.”
Before the first PCSK9 inhibitor was launched, the company implemented it Cholesterol Care Value Program that works to ensure only those who really need the treatment receive it, as statins are still the best option for most high cholesterol patients, Express Scripts said. The company plans to cap plan costs for PCSK9 inhibitors in 2016 for patients in the CCV program.
“Aligned with our clients, we have achieved a more balanced marketplace, which has led to more collaborative discussions with manufacturers like Amgen, Regeneron and Sanofi, who share our interest in delivering innovative treatments to patients when clinically appropriate,” Miller said. “As a result, we are confident that we have received the best price possible for both products, without needing to exclude either.”
Accredo Specialty Pharmacy will provide patients with Praulent and Repatha, and patients will have access to pharmacists and nurses to train them how to use the injectable drugs, and will offer support and monitoring to ensure proper adherence.
“By providing specialized patient care to improve adherence, predicting which patients will best respond by using the industry's most robust set of pharmacy data, and leveraging our focused scale to drive affordability, Express Scripts uniquely creates the most value for patients and plan sponsors,” Miller said.